EP Patent

EP3953332A1 — Tricyclic degraders of ikaros and aiolos

Assigned to C4 Therapeutics Inc · Expires 2022-02-16 · 4y expired

What this patent protects

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

USPTO Abstract

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP3953332A1
Jurisdiction
EP
Classification
—
Expires
2022-02-16
Drug substance claim
No
Drug product claim
No
Assignee
C4 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.